Due to their complexity and size, oligonucleotides, including ASOs, AOCs and siRNA, incur unique pain points in drug delivery. Yet, this struggle has highlighted urgency and opportunities for growth. In an industry study in April this year, effective delivery of oligos was the highest predicted major advancement over the next five years.
This ebook gathers insights and discussion from the likes of Roche, Alnylam Pharmaceuticals and Dyne Therapeutics on the latest work in targeted delivery methods for therapeutic oligonucleotides. Exploring common drug targets, delivery vehicles and strategies, we highlight key challenges in oligo drug delivery and notable solutions uncovered in leading projects.
Biotechnology writer David Orchard-Webb opens with a whitepaper presenting the key challenges in the oligo field so far, followed by summaries of scientific presentations on muscle tissue targeting and delivery strategies for LNA ASOs and RNAi. The final part explores a discussion between industry experts on targeted delivery of oligonucleotides, including approaches to different target tissues and the use of peptides and antibodies.
Explore or download the interactive eBook by clicking on the image above or here.
A sneak peek of what's inside...
- Targeted Drug Delivery of Therapeutic Oligonucleotides: A Whitepaper
- Muscle Targeted Delivery of Therapeutic Oligonucleotides
- Disruptive Delivery Approaches for LNA ASOs: Evaluation of Bovine Milk EVs and LNPs as Oral DDS
- Progress of RNAi in Extrahepatic Tissues
- Targeted Delivery of Oligonucleotides: Tissue-specific Challenges and Novel Conjugation
Explore or download the interactive eBook by clicking on the image above or here.